Osteoporosis in Iran, overview and management

Iranian Journal of Public Health

Volumn 36, Issue SUPPL., 2007, Pages 1-13

  Larijani, B ^a   Resch, H ^b   Bonjour, J P ^c   Aghai Meybodi, H R ^a   Mohajery Tehrani, M R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Iran; Management; Osteoporosis

Indexed keywords

EID: 34848817343     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94: 646-50.
2. World Health Organization (1994). Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. World Health Organization: Geneva.
3. Cooper C, Melton LJ (2001). Magnitude and impact of osteoporosis and fractures. In: Osteoporosis. Eds, Marcus R, Feldman D, Kelsey J. 2nd ed, Academic Press Inc, San Diego, pp. 557-67.
4. Guidelines for preclinical evaluation and clinical trials in osteoporosis (1998). World Health Organization, Geneva: 59.
5. Shepherd A J (2004). An overview of osteoporosis. Altern Ther Health Med, 10: 26-34.
6. Chapuy MC, Arlot ME, Duboeuf F (1992). Vitamine D3 and calcium to prevent hip fractures in elderly women. N Engl J Med, 327(23): 1637-42.
7. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 yr of age or older. N Engl J Med, 337(10): 670-676.
8. Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. (2004). Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health, 4(1): 38.
9. McKenna MJ (1992). Differences in vitamin D status between countries in young adults and the elderly. Am J Med, 93: 69-71.
10. Abdollah Shamshirsaz A, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Habibzadeh MR, Hashemi SR, et al. (2003). Metabolic and Endocrinological complication in Beta-thalassemia major: A multicenter study in Tehran. BMC Endocr Disord, 3(1): 4.
11. Larijani B, Bekheirnia MR, Soltani A, Khalili-Far A, Adibi H, Jalili RB (2004). Bone mineral density is related to blood pressure in men. Am J Hum Biol, 16: 168-71.
12. Hossein-nezhad A, Soltani A, Rahimi I, Shafaie A, Maghbooli Z, Larijani B (2003). Relation between tea drinking and bone mineral density. Tabib-Shargh, 2: 29-38 (In Farsi).
13. Haghighian A, Tahbaz F, Hosseinnezhad A, Shafaei A, Sedaght M, Kimiagar M, Larijani B (2005). Effect of soy protein on bone metabolism biomarkers in post-menopausal women with osteopenia. Nutr J, 29(4): 30.
14. Bekheirnia MR, Abdollah Shamshirsaz A, Kamgar M, Bouzari N, Erfanzadeh G, Larijani B, et al. (2004). Serum zinc and its relation to bone mineral density in beta thalassemic adolescents. Biol Trace Elem Res, 97: 215-24.
15. Marshall D, Johnell O, Wedel H (1996). Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMA, 312: 1254-9.
16. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE (1995). Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Eng Med, 332: 767-73.
17. Wasnich RD, Davis JW, Ross PD (1994). Spine fracture risk is predicted by nonspine fractures. Osteoporos Int, 4:1-5.
18. Davis JW, Grove JS, Wasnich RD, Ross PD (1999). Spatial relationships between prevalent and incident spine fractures. Bone, 24: 261-4.
19. Ismail AA, Cockerill W, Cooper C, Finn JD, Abendroth K, Parisi G (2001). Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European prospective osteoporosis. Osteoporos Int, 12: 85-90.
20. Klotzbuecher CM, Ross PD, Landsman P, Abbott TAI, Berger M (2000). Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. Bone Miner Res, 15: 721-39.
21. Kanis JA, Johnell O, De Laet C (2004). A meta-analysis of previous fracture and subsequent fracture risk. Bone, 35: 375-82.
22. Ross PD, Davis JW, Epstein RS, Wasnich RD (1991). Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med, 114: 919-23.
23. Tromp AM, Smit JH, Deeg DJH, Bouter LM, Lips P (1998). Predictors for falls and fractures in the longitudinal aging study Amsterdam. J Bone Miner Res, 13: 1932-39.
24. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR (1999). Defining incident vertebral deformity, a prospective comparison of several] approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res, 14: 90-101.
25. Fox KM, Cummings SR, Williams E, Stone K (2000). Study of Osteoporotic Fractures. Femoral neck and intertrochanteric fractures have different risk factors, a prospective study. Osteoporos Int, 11:1018-24.
26. Ettinger B, Black DM, Mitlak BH, Kniekerbocker RK, Nickelsen T, Genant HK (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA, 282: 637-45.
27. McClung MR, Geusens P, Miller PD, Zippel H, Bensen W, Roux C (2001). Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med, 344: 333-40.
28. Sambrook P, Cooper C (2006). Osteoporosis. Lancet;367: 2010-18
29. Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK (1990). Appendicular bone density and age predict hip fracture in women. JAMA, 263: 665-68.
30. Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, Brown JP (2001). Evaluation of decision rules for referring women for bone densitometry by dual-energy X-ray absorptiometry. JAMA, 286: 57-63.
31. AACE Osteoporosis Guidelines (2003). Endocr Pract, 9 (6): 544-64.
32. Torgerson DJ, Campbell MK, Thomas RE, Reid DM (1996). Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res, 11: 293-7.
33. Larijani B (2004). An overview of osteoporosis in Iran. 1st international osteoporosis seminar in Iran. Tehran, Iran.
34. Cooper C, Atkinson EJ, O'Fallon WM, Melton LU (1992). Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res, 7: 221-27.
35. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG (2000). Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum, 29: 228-51.
36. Cooper C, Walker-Bone K, Arden N (2000). Novel insights into the pathogenesis of the role of intrauterine programming. Rheumatology, 39: 1312-15.
37. Cooper C, Eriksson JG, Forson T (2001). Maternal height, childhood growth and risk of hip fracture in later life: a longitudinal study. Osteoporos Int, 12: 623-629.
38. Anderson FH, Francis RM, Selby PL (1998). Sex hormones and osteoporosis in men. Calcif Tissue Int, 62: 185-88.
39. Amin S, Yuquing Z, Clark T (2000). Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann Intern Med, 133: 951-63.
40. Barrett-Conner E, Mueller JE, von Muhlen DG (2000). Low levels of oestradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab, 85: 219-23.
41. Iki M, Kagamimori S, Kagawa Y (2001). Bone Mineral Density of the Spine, Hip and Distal Forearm in Representative Samples of the Japanese Female Population: Japanese Population-Based Osteoporosis (JPOS) Study. Osteoporos Int, 12: 529-37.
42. Tenenhouse A, Joseph L, Kreiger N (2000). Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int, 11: 897-904.
43. Lau EM, Lee JK, Suriwongpaisal P (2001). The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int, 12: 239-43.
44. El-hajj Fuleihan G, Baddoura R, Awada H (2002). Low Peak Bone Mineral Density in Healthy Lebanese Subjects. Bone, 31(4): 520-28.
45. Larijani B, Soltani A, Pajouhi M (2002). Bone mineral density variation in 20-69 y/o population of Tehran/Iran. Iranian South Medical Journal, 5: 41-49 (In Farsi).
46. National Osteoporosis Foundation (2003). Physician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation, p 37.
47. Yeap SS, pearson D, cawte SA (1998). The relationship between bone mineral density and ultrasound in postmenopausal and osteoporotic women. Osteoporosis Int, 8(2): 141-146.
48. Dabbaghmanesh MH, Pajouhi M, Larijani B (2002). How is the agreement of QUS of heel and DXA in diagnosis of osteoporosis. Iranian South Medical Journal, 5: 50-55 (In Farsi).
49. Larijani B, Dabbaghmanesh M.h., Sedaghat M, Akrami M, Hamidi Z, rahimi I (2004). Defining cut-off values for diagnosis of osteoporosis in postmenopausal women by quantitative heel ultrasonography (QUS). Iranian J of Endocrin Met, 69: 39-45.
50. Sedaghat M, Hamidi Z, Soltani A, Rahimi E, Maghbooli J, Larijani B (2004). Defining cut-off values for diagnosis of osteoporosis in postmenopausal women by quantitative phalanx ultrasonography (QUS). 1st international osteoporosis seminar in Iran. Tehran, Iran.
51. Bouillon R, Carmeliet G, Daci E (1998). Vitamin D Metabolism and action. Osteoporos Int, suppl 2: S13-S19.
52. Bouillon R (2001). Vitamin D: Photosynthesis, metabolism, and action to clinical applications. In: Endocrinology. Eds, Degroot L, Jameson JL, Burger HG. 3rd ed, WB Saunders Inc. Philadelphia, pp. 1009-28.
53. Du X, Greenfield H, Fraser DR (2001). Vitamin D deficiency and associated factors in adolescent girl in Beijing. Am J Clin Nutr, 74: 494-500.
54. Alagol F, Shihadeh Y, Boztepe H (2000). Sunlight exposure and vitamin D in Turkish women. J Endocrinol Invest, 23: 173-77.
55. Gowami R, Gupta N, Gosuwami D (2000). Prevalence and significance of low 25-Hydroxy vitamin D concentrations in healthy subjects in Dehli. Am J Clin Nutr, 72: 422-75.
56. Azizi F, Rais-Zadeh F, Mir Said Ghazi A (2000). Vitamin D deficiency in a group of Tehran Population. Research in Medicine, 4: 291-303.
57. Sedrani SH, Elidrissy AW, Arabi KM (1983). Sunlight and vitamin D status in normal Saudi subjects. Am J Clin Nutr, 38: 129-32.
58. Sedrani SH (1984). Low 25-Hydroxy vitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. Ann Nutr Metab, 28: 181-85.
59. Taha S, Dost S, Sedrani S (1984). 25-hydroxy vitamin D and total calcium extra ordinarily low plasma concentrations in Saudi mothers and their neonates. Pediatr Res, 18: 739-41.
60. Fonseca V, Tongia R, el-Hasmi M (1984). Exposure to sunlight and vitamin D deficiency in Saudi Arabian women. Post-grad Med J, 60: 589-91.
61. Lips P (2001). Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev, 22: 477-501.
62. Torabi P, Sheikholeslam R, Larijani B (2004). Vitamin d fortification in Iran. 8th Iranian Nutrition conference. Tehran, Iran.
63. Christodoulou C, Cooper C (2003). What's osteoporosis? Postgraduate Med J, 79: 133-38.
64. Cummings SR, Melton LJ (2002). Epidemiology and outcomes of osteoporotic fractures. Lancet, 359: 1761-67.
65. Royal College of Physicians of London (1989). Fractured neck of femur: prevention and management. London: Royal College of Physicians.
66. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001). Osteoporosis prevention, diagnosis, and therapy. JAMA, 285(6): 785-95.
67. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1995). Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med, 98: 331-35.
68. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005). Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA, 293: 2257-64.
69. Munger RG, Cerhan JR, Chiu BC (1999). Prospective study of dietary protein intake and risk of hip fracture in post-menopausal women. Am J Clin Nutr, 69: 147-52.
70. Hernandez-Avila M, Colditz GA, Stampfer MJ, Rosner B, Speizer FE, Willett WC (1991). Caffeine, moderate alcohol intake and risk of fractures of the hip and forearm in middle-aged women. Am J Clin Nutr, 54: 157-63.
71. Devine A, Criddle RA, Dick IM, Kerr DA, Prince RL (1995). A longitudinal study of the effect of sodium and calcium intakes on regional bone density in post-menopausal women. Am J Clin Nutr, 62: 740-45.
72. Ebrahimof S, Hoshyarrad A, Hossein-Nezhad A, Zandi N, Larijani B, Kimiagar M (2005). ARYA Journal, 1(3): 183-87.
73. Byrjalsen I, Haarbo J, Christiansen C (1993). Role of cigarette smoking on the post-menopausal endometrium during sequential estrogen and progestogen therapy. Obstet Gynecol, 81(6): 1016-20.
74. Greendale GA, Wells B, Marcus R, Barrett-Connor E (2000). How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal Estrogen/Progestin interventions trial. Arch Intern Med, 160(20): 3065.
75. Cranney A, Guyatt G, Griffith L (2002). Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev, 23: 570-78.
76. Liberman UA, Weiss SR, Broll J (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 333: 1437-43.
77. Cummings SR, Black DM, Thompson DE (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280: 2077-82.
78. Schnitzer T, Bone HG, Crepaldi S (2000). Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg in the treatment of osteoporosis. Aging Clin Exp Res, 12: 1-12.
79. Brown JP, Kendler DL, McClung MR (2002). The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tiss Int, 71: 103-11.
80. Johnell O, Scheele W, Lu Y, Reginster J, Need A, Seeman E (2002). Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocr Metab, 87: 985-92.
81. Sambrook PN, Geusens P, Ribot C (2004). Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med, 255: 503-11.
82. Rosen CJ, Hochberg MC, Bonnick SL (2005). Treatment with once weekly alendronate 70mg compared with once-weekly risedronate 35mg in women post-menopausal osteoporosis: a randomized double-blind study. J Bone Miner Res, 20: 141-51.
83. Levine J, Nelson D (1997). Esophageal stricture associated with alendronate therapy. Am J Med, 102(5): 489-92.
84. Bone HG, Greenspan SL, McKeever C (2000). Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab, 85(2): 720-26.
85. Ettinger B, San Martin J, Crans G, Pavo I (2004). Differential efects of teriparatide on bone mineral density after treatment with raloxifene or alendronate. J Bone Miner Res, 19: 745-51.
86. The writing group of PEPI (1996). Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA, 276: 1389-96.
87. Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA, 288(3): 321-33.
88. Riggs BL, Hartmann LC (2003). Selective estrogen-receptor modulators mechanisms of action and application to clinical practice. N Engl J Med, 348(7): 618-21.
89. Cauley J, Norton L, Lippman M, Eckert S, Krueger K, Purdie D (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results form the MORE trial. Breast Cancer Res Treat, 65(2): 125-134.
90. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA, 281(23): 2189-97.
91. Dempster DW, Cosman F, Parisien M (1993). Anabolic actions of parathyroid hormone on bone. Endocr Rev, 14(6): 690-709.
92. Neer RM, Arnaud CD, Zanchetta JR (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 344(19): 1434-41.
93. Chesnut CH III, Silverman S, Andriano K, Genant HK, Gimona A, Harris S (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med, 109(4): 267-76.
94. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P (1998). Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteo-poros Int, 8(1): 4-12.